Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Everolimus in Unresectable Hepatocellular Carcinoma
NCT01005199Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2009
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of everolimus in hepatocellular carcinoma (HCC), sponsored by Swiss Group for Clinical Cancer Research. Started Nov 2009; status: completed.
02
Drugs
everolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01005199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01005199.